FREMONT, Calif., March 8 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(PDL) (Nasdaq: PDLI) today announced that Andrew Guggenhime, chief
financial officer, will participate in the upcoming Cowen and Company 27th
Annual Healthcare Conference in Boston, Mass. on Thursday, March 15, 2007,
at 8:45 a.m. Eastern time.
The live webcast of the conference call will be available through the
PDL website: http://www.pdl.com. Please connect to this website at least 15
minutes prior to the live webcast to allow time for any software download
that may be needed to hear the webcast. A replay will be available at
http://www.pdl.com starting approximately one hour after completion of the
webcast.
About PDL BioPharma
PDL BioPharma, Inc. is a biopharmaceutical company focused on
discovering, developing and commercializing innovative therapies for severe
or life- threatening illnesses. Commercially focused in the acute-care
hospital setting, PDL markets and sells its portfolio of leading products
in the United States and Canada. A pioneer of antibody humanization
technology, PDL promotes this technology through licensing agreements and
clinical development of its own diverse pipeline of investigational
compounds. PDL's research platform centers on the discovery and development
of antibodies to treat cancer and autoimmune diseases. For more
information, please visit http://www.pdl.com.
NOTE: PDL BioPharma and the PDL logo are considered trademarks of PDL
BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
 back to top
Related links:
http://www.pdl.com/
CONTACT:
Ami Knoefler, Corporate and Investor
Relations, +1-510-284-8851, or ami.knoefler@pdl.com, or Jean
Suzuki, Corporate Relations, +1-510-574-1550, or
jean.suzuki@pdl.com, both of PDL BioPharma, Inc.
|
